CBX1 and ovarian carcinoma: In our research, we found that upregulation of CBX1 expression was obviously associated with worse prognosis in all patients with ovarian carcinoma, especially for those with the serous histological type, grade II, grade III, and all stages and for those treated with Taxol, platin, or Taxol+platin.